Maiken Keson-Brookes - 01 Mar 2024 Form 4 Insider Report for Mural Oncology plc (MURA)

Role
Chief Legal Officer and Secretary
Signature
/s/ Maiken Keson-Brookes
Issuer symbol
MURA
Transactions as of
01 Mar 2024
Net transactions value
$0
Form type
4
Filing time
04 Mar 2024, 17:18:23 UTC
Previous filing
18 Dec 2023
Next filing
18 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MURA Ordinary Shares Award $0 +16,800 +58% $0.000000 46,007 01 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MURA Stock Option (right to buy) Award $0 +31,200 $0.000000 31,200 01 Mar 2024 Ordinary Shares 31,200 $5.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of ordinary shares issuable under 16,800 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2024, subject to the reporting person's continued service with the Issuer.
F2 This option was granted on March 1, 2024. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2025 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer.

Remarks:

Chief Legal Officer and Secretary